INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
486.1 EUR
+5.1 (+1.06%)
Overall IUI1 gets a fundamental rating of 6 out of 10. We evaluated IUI1 against 65 industry peers in the Health Care Equipment & Supplies industry. IUI1 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IUI1 is valued quite expensively, but it does show have an excellent growth rating. These ratings could make IUI1 a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
IUI1 had positive earnings in each of the past 5 years.
In the past 5 years IUI1 always reported a positive cash flow from operatings.
1.2 Ratios
IUI1 has a better Return On Assets (14.19%) than 92.42% of its industry peers.
The Return On Equity of IUI1 (16.12%) is better than 83.33% of its industry peers.
IUI1 has a Return On Invested Capital of 11.69%. This is amongst the best in the industry. IUI1 outperforms 83.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is in line with the industry average of 9.71%.
The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(11.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
Looking at the Profit Margin, with a value of 28.58%, IUI1 belongs to the top of the industry, outperforming 98.48% of the companies in the same industry.
In the last couple of years the Profit Margin of IUI1 has declined.
IUI1 has a better Operating Margin (29.44%) than 98.48% of its industry peers.
IUI1's Operating Margin has declined in the last couple of years.
IUI1 has a Gross Margin of 66.38%. This is in the better half of the industry: IUI1 outperforms 74.24% of its industry peers.
IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
IUI1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, IUI1 has more shares outstanding
Compared to 5 years ago, IUI1 has more shares outstanding
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.33
WACC8.8%
2.3 Liquidity
IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.97, IUI1 belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.
A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
The Quick ratio of IUI1 (4.20) is better than 96.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.12% over the past year.
Measured over the past years, IUI1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.48% on average per year.
IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.18%.
IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
The Earnings Per Share is expected to grow by 15.47% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.12% on average over the next years. This is quite good.
EPS Next Y20.12%
EPS Next 2Y16.31%
EPS Next 3Y15.91%
EPS Next 5Y15.47%
Revenue Next Year21.33%
Revenue Next 2Y18.1%
Revenue Next 3Y16.47%
Revenue Next 5Y14.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IUI1 is valuated quite expensively with a Price/Earnings ratio of 66.14.
Compared to the rest of the industry, the Price/Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 62.12% of the companies listed in the same industry.
IUI1 is valuated expensively when we compare the Price/Earnings ratio to 26.39, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 57.41, the valuation of IUI1 can be described as expensive.
Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 72.73% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.84, IUI1 is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.14 | ||
| Fwd PE | 57.41 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than the industry average as 68.18% of the companies are valued more cheaply.
IUI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 88.86 | ||
| EV/EBITDA | 56.07 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.91% in the coming years.
PEG (NY)3.29
PEG (5Y)5.76
EPS Next 2Y16.31%
EPS Next 3Y15.91%
5. Dividend
5.1 Amount
IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (12/19/2025, 7:00:00 PM)
486.1
+5.1 (+1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.16%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap172.32B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts78
Price Target524.41 (7.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)0.58%
PT rev (3m)4.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.25%
EPS NY rev (1m)0.16%
EPS NY rev (3m)5.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.69%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.14 | ||
| Fwd PE | 57.41 | ||
| P/S | 21 | ||
| P/FCF | 88.86 | ||
| P/OCF | 68.17 | ||
| P/B | 11.84 | ||
| P/tB | 12.09 | ||
| EV/EBITDA | 56.07 |
EPS(TTM)7.35
EY1.51%
EPS(NY)8.47
Fwd EY1.74%
FCF(TTM)5.47
FCFY1.13%
OCF(TTM)7.13
OCFY1.47%
SpS23.15
BVpS41.05
TBVpS40.21
PEG (NY)3.29
PEG (5Y)5.76
Graham Number82.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC8.8%
ROIC/WACC1.33
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.31%
EPS Next 3Y15.91%
EPS Next 5Y15.47%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.33%
Revenue Next 2Y18.1%
Revenue Next 3Y16.47%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.62%
EBIT Next 3Y24.72%
EBIT Next 5Y20.46%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
What is the valuation status of INTUITIVE SURGICAL INC (IUI1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Price/Earnings (PE) ratio for INTUITIVE SURGICAL INC (IUI1.DE) is 66.14 and the Price/Book (PB) ratio is 11.84.
What is the earnings growth outlook for INTUITIVE SURGICAL INC?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 20.12% in the next year.